Board of Advisors  Randall Barton, Ph.D. Dr. Barton has had almost 20 years of drug discovery experience with Boehringer Ingelheim Pharmaceuticals, primarily in the areas of immunological and inflammatory diseases as well as cardiovascular and metabolic diseases.  He had responsibility for target identification and validation as well as lead optimization and early stage development of both small molecule and biological drug candidates including monoclonal antibody and gene and cell therapy.  More recently, he has been involved in discovery and development functions in oncology and virology in the biotech industry.  Prior to joining Boehringer Ingelheim, Dr. Barton held a faculty position at the University of Connecticut Medical School and currently has an adjunct position.  He is the author of more than 75 publications and patents. Robert Rothlein, Ph.D. Dr. Rothlein obtained his Ph.D. in immunology at the Sloan-Kettering Division of The Cornell Graduate School of Medical Science in 1982; and in 1985 completed his post-doctoral fellowship at the Dana Farber Cancer Institute in the laboratory of Dr. Timothy Springer where he identified ICAM-1 as a ligand for the CD18 family of adhesion molecules. Dr. Rothlein then moved to Boehringer Ingelheim Pharmaceuticals Inc. in Ridgefield, Connecticut where he held various positions of increasing responsibility. Dr. Rothlein's research at Boehringer Ingelheim focused primarily on the discovery of antagonists of LFA-1/ICAM-1 interactions and on the biology of these two molecules. He is an inventor on 13 patents and an author on more than 100 publications.